Clinical Trial

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).
Trial Details
NCT Number NCT05528055
Lead Sponsor Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions Solid Tumor, Non Hodgkin Lymphoma
Enrollment 122 participants
Start Date 2022-05-18
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2022-09-06